Stem cell shot aims to reverse frailty in seniors
NCT ID NCT07144072
First seen Oct 31, 2025 · Last updated May 15, 2026 · Updated 21 times
Summary
This early-stage study tests the safety of a new stem cell treatment called HeXell-2020 in 12 older adults (ages 60-85) with mild to moderate frailty. Participants receive a single intravenous dose, and researchers monitor for side effects and changes in physical function like walking ability. The goal is to see if the treatment is safe enough for further testing.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for FRAILTY IN OLDER ADULTS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.